AA
ALXN

Antipodean Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Antipodean Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-111,911
Closed -$13M – 33
2013
Q3 		$13M Buy
+111,911
New +$12.3M 1.36% 23

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Antipodean Advisors's ALXN Position: Q4 2013 in Review

Antipodean Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2013, closing a stake of 111,911 shares — an estimated $13M sold.

Antipodean Advisors first reported a position in ALXN in Q3 2013 and held it in 1 quarter. The position peaked at $13M in Q3 2013. 462 funds tracked by Wall St. Rank hold ALXN as of Q4 2013.

  • Antipodean Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Antipodean Advisors sold 111,911 Alexion Pharmaceuticals shares in Q4 2013, an estimated $13M.
  • Antipodean Advisors first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Antipodean Advisors's Alexion Pharmaceuticals position peaked at $13M in Q3 2013.
  • 462 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2013.

Based on Antipodean Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.